You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Details for Patent: 8,236,766


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,236,766 protect, and when does it expire?

Patent 8,236,766 protects KORSUVA and is included in one NDA.

This patent has forty-nine patent family members in twenty-five countries.

Summary for Patent: 8,236,766
Scope and claims summary:
Title:Uses of synthetic peptide amides
Abstract: The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P.sub.450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: ##STR00001## wherein Xaa is a D-amino acid and G is selected from the following three groups: ##STR00002## The compounds are useful in the prophylaxis and treatment of pain, pruritus and inflammation associated with a variety of diseases and conditions.
Inventor(s): Schteingart; Claudio D. (San Diego, CA), Menzaghi; Frederique (Rye, NY), Jiang; Guangcheng (San Diego, CA), Alexander; Roberta Vezza (San Diego, CA), Sueiras-Diaz; Javier (La Jolla, CA), Spencer; Robert H. (New Hope, PA), Chalmers; Derek T. (Riverside, CT), Luo; Zhiyong (New City, NY)
Assignee: Cara Therapeutics, Inc. (Shelton, CT)
Application Number:12/480,059
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,236,766

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cara Therap KORSUVA difelikefalin acetate SOLUTION;INTRAVENOUS 214916-001 Aug 23, 2021 RX Yes Yes 8,236,766 ⤷  Subscribe TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD) ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,236,766

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2064228 ⤷  Subscribe 301199 Netherlands ⤷  Subscribe
European Patent Office 2064228 ⤷  Subscribe CA 2022 00045 Denmark ⤷  Subscribe
European Patent Office 2064228 ⤷  Subscribe PA2022522 Lithuania ⤷  Subscribe
European Patent Office 2064228 ⤷  Subscribe LUC00282 Luxembourg ⤷  Subscribe
European Patent Office 2064228 ⤷  Subscribe 2022C/546 Belgium ⤷  Subscribe
European Patent Office 2064228 ⤷  Subscribe C20220035 00379 Estonia ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.